Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloperidone LAI in Schizophrenia
NCT04712734Phase 1Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jan 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iloperidone in schizophrenia, sponsored by Vanda Pharmaceuticals Inc. Primary endpoints: Pharmacokinetics of iloperidone and metabolites at 24 weeks and Assessment of safety and tolerability at 24 weeks. Started Jan 2021; status: completed.
02
Drugs
iloperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04712734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712734.